Troxacitabine-based therapy of refractory leukemia

Medicine and Dentistry

• Troxacitabine 100%
• Inpatient 66%
• Leukemia 33%
• Acute Myeloid Leukemia 33%
• Cytarabine 33%
• Nucleoside 33%
• Development 16%
• Spontaneous Remission 16%
• Mucositis 16%
• Toxicity 16%
• Combination Therapy 16%
• Tumor Cell 16%
• Hematologic Malignancy 16%
• Cytotoxicity 16%
• Chronic Myelogenous Leukemia 16%
• Lymphoproliferative Disease 16%
• Topotecan 16%
• Fludarabine 16%
• Idarubicin 16%
• Hand Foot Syndrome 16%
• Patient 16%
• Nucleoside Analogue 16%

INIS

• patients 83%
• refractories 83%
• myeloid leukemia 50%
• nucleosides 50%
• leukemia 33%
• therapy 16%
• tumor cells 16%
• diseases 16%
• toxicity 16%
• transport 16%
• malignancies 16%
• doses 16%
• hands 16%
• stereochemistry 16%